{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:23:11Z","timestamp":1774988591645,"version":"3.50.1"},"reference-count":165,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T00:00:00Z","timestamp":1630886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J of Neuroscience Research"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Endocannabinoid system has been extensively studied in recent decades, particularly the cannabinoid receptors CB1 and CB2, due to their important role in neuroinflammation. Among these, CB2 has gained prominence due to its selective overexpression in glial cells during neuroinflammation. In contrast to CB1 agonists, CB2 agonists have no side effects such as ataxia, hypothermia, euphoria, psychological, or addiction liabilities. CB2 and its selective agonists' above\u2010mentioned unique properties have become a research focus in neurodegenerative disorders such as Alzheimer's disease (AD). The review discusses the neuroprotective role of CB receptors, particularly CB2, in AD, as well as the significance and limitations of this research.<\/jats:p>","DOI":"10.1002\/jnr.24933","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T06:57:24Z","timestamp":1630911444000},"page":"2888-2905","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cannabinoid receptor 2 selective agonists and Alzheimer's disease: An insight into the therapeutic potentials"],"prefix":"10.1002","volume":"99","author":[{"given":"Sai Varshini","family":"Magham","sequence":"first","affiliation":[{"name":"Department of Pharmacology JSS College of Pharmacy JSS Academy of Higher Education and Research Ooty India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2666-0878","authenticated-orcid":false,"given":"Praveen","family":"Thaggikuppe krishnamurthy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology JSS College of Pharmacy JSS Academy of Higher Education and Research Ooty India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neenu","family":"Shaji","sequence":"additional","affiliation":[{"name":"Department of Pharmacology JSS College of Pharmacy JSS Academy of Higher Education and Research Ooty India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalithkumar","family":"Mani","sequence":"additional","affiliation":[{"name":"Department of Pharmacology JSS College of Pharmacy JSS Academy of Higher Education and Research Ooty India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9154-2248","authenticated-orcid":false,"given":"Shivaramakrishnan","family":"Balasubramanian","sequence":"additional","affiliation":[{"name":"Department of Pharmacology JSS College of Pharmacy JSS Academy of Higher Education and Research Ooty India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2021,9,6]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"A Comparative Study of KHK6188\u2014Full Text View\u2014ClinicalTrials.gov [Internet]. (2012). [cited 2021 February 10].https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01544296"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/2326409817723667"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0122843"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18040691"},{"key":"e_1_2_11_6_1","unstructured":"Alzheimer's Statistics[Internet]. (2019). Alzheimers.net. [cited 2021 January 29].https:\/\/www.alzheimers.net\/resources\/alzheimers\u2010statistics"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20081837"},{"key":"e_1_2_11_8_1","unstructured":"Arena pharmaceuticals 2019Arena Pharmaceuticals Presents Preclinical and Early Clinical Development Data for Olorinab at Crohn's & Colitis Congresse"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2014.00037"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-141014"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00243"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-130137"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00729.x"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.074013"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.23074"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/78682"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/jnc.14098"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.23-35-11136.2003"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4814-06.2007"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.11.052"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1097\/ACO.0000000000000616"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4814-07.2008"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1996.0704p.x"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1421420112"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1471-4892(02)00011-5"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/syn.20569"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2017.206"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1567-5769(01)00147-3"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2017.00030"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.00124"},{"key":"e_1_2_11_31_1","unstructured":"CB1 Cannabinoid Receptor Modulation Using Allosteric Ligands[Internet]. (2017). CBD testers. [cited 2021 May 31].https:\/\/cbdtesters.co\/2017\/06\/27\/cb1\u2010cannabinoid\u2010receptor\u2010modulation\u2010using\u2010allosteric\u2010ligands\/"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.10.042"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-051116-052358"},{"key":"e_1_2_11_34_1","unstructured":"Corbus Announces Publication of Lenabasum Systemic Sclerosis Double\u2010Blind Placebo\u2010Controlled Phase 2 Clinical Trial Results in Arthritis & Rheumatology [Internet]. (2018). [cited 2021 January 9].https:\/\/ir.corbuspharma.com\/press\u2010releases\/detail\/326\/corbus\u2010announces\u2010publication\u2010of\u2010lenabasum\u2010systemic"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.2014.918603"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.03.013"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-019-0333-5"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1469-06.2006"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.114.094649"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.116.232561"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.115"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.npp.1301643"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-0082(02)00080-1"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-2-29"},{"key":"e_1_2_11_45_1","unstructured":"Eli Lilly and Company. (2020 May).A proof of concept study of the effects of LY2828360 in the treatment of patients with osteoarthritic knee pain[Internet]. clinicaltrials.gov; [cited 2021 January 7]. Report No.: NCT01319929.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01319929"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2006.06.012"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.107.121566"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/mp060066m"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/glia.10177"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2012.05.013"},{"issue":"3","key":"e_1_2_11_51_1","first-page":"443","article-title":"Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors","volume":"48","author":"Felder C. C.","year":"1995","journal-title":"Molecular Pharmacology"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.14382"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2006.11.001"},{"key":"e_1_2_11_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2016.08.017"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2014.04.034"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules24173164"},{"key":"e_1_2_11_57_1","unstructured":"GlaxoSmithKline. (2017 July).A double\u2010blind placebo controlled cross\u2010over study of the effects of the CB2 compound of GW842166 in patients with osteoarthritis[Internet]. clinicaltrials.gov; [cited 2021 January 7]. Report No.: NCT00479427.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00479427"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/8152373"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pnpbp.2015.03.017"},{"key":"e_1_2_11_60_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-007-0015-0"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(99)00402-1"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0707531"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00456"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm4005626"},{"key":"e_1_2_11_65_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2013\/825065","article-title":"Oxidative stress induces mitochondrial DNA damage and cytotoxicity through independent mechanisms in human cancer cells","volume":"2013","author":"Han Y.","year":"2013","journal-title":"BioMed Research International"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.201709069"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.25.14228"},{"key":"e_1_2_11_68_1","unstructured":"Home[Internet]. (2014).Arena pharmaceuticals. [cited 2021 February 10].https:\/\/www.arenapharm.com\/"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1007\/3-540-26573-2_2"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5b00739"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.01.008"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557054368844"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.2174\/156802608783498014"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2016.0037"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-0696-x"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10571-013-9984-x"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00321"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.11.006"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2018.12.026"},{"key":"e_1_2_11_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjpain.2012.08.004"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells7120274"},{"key":"e_1_2_11_82_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0155076"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2016.00294"},{"key":"e_1_2_11_84_1","unstructured":"KeyNeurotek pharmaceuticals reports positive phase I data of its cannabinoid receptor\u2010agonist[Internet]. (2008). [cited 2021 Janaury 9].https:\/\/www.bionity.com\/en\/news\/81960\/keyneurotek\u2010pharmaceuticals\u2010reports\u2010positive\u2010phase\u2010i\u2010data\u2010of\u2010its\u2010cannabinoid\u2010receptor\u2010agonist.html"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trci.2018.06.014"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0705304"},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2016.03.015"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.2119\/molmed.2013.00140"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-3084(00)00194-8"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.85814"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986712801323207"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-017-0192-x"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2019.134286"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/9817089"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(00)00615-4"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.2337\/db09-0979"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-018-1174-9"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00002"},{"key":"e_1_2_11_99_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-018-0173-1"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrn4036"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/130639"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1124\/mol.111.071290"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.2004.04460.x"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.01948.x"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-2294-9_5"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00487"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1038\/365061a0"},{"key":"e_1_2_11_108_1","unstructured":"Muthuppalaniappan M. Balasubramanian G. Gullapalli S. Joshi N. K. &Narayanan S.(2006).Novel cannabinoid receptor ligands pharmaceutical compositions containing them and process for their preparation[Internet]. WO2006129178A1 [cited 2021 January 9].https:\/\/patents.google.com\/patent\/WO2006129178A1\/en"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2016.00406"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.2174\/09298673113206660296"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01487"},{"key":"e_1_2_11_112_1","unstructured":"Page not found[Internet]. (2019). Cara therapeutics. [cited 2021 February 10].http:\/\/www.caratherapeutics.com\/pipeline\u2010technology\/cb\u2010agonists\/https:\/\/doi.org\/10.6084\/m9.figshare.7619327"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awp239"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M111.291294"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroscience.2019.08.001"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.48.6.859"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2006.06.013"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1460-9568.2009.06764.x"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4540-04.2005"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-006-0508-y"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1089\/jpm.2018.0528"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddy154"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.2174\/092986710790980005"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2018.07.049"},{"issue":"5","key":"e_1_2_11_125_1","first-page":"5","article-title":"Cannabinoid receptor type 2 activation induces a microglial anti\u2010inflammatory phenotype and reduces migration via MKP induction and ERK dephosphorylation","volume":"4","author":"Romero\u2010Sandoval E. A.","year":"2009","journal-title":"Molecular Pain"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.aap.2007.10.011"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881111408958"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.4172\/pharmaceutical-sciences.1000397"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm050565b"},{"key":"e_1_2_11_130_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/432607"},{"issue":"15","key":"e_1_2_11_131_1","first-page":"5784","article-title":"Inhibition of glioma growth in vivo by selective activation of the CB(2) cannabinoid receptor","volume":"61","author":"S\u00e1nchez C.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2011.05.012"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2010.00773.x"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-59745-503-9_6"},{"key":"e_1_2_11_135_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10312"},{"key":"e_1_2_11_136_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2016.01.011"},{"key":"e_1_2_11_137_1","unstructured":"Shionogi. (2018 May).A multicenter randomized double\u2010blind placebo\u2010controlled parallel\u2010group efficacy and safety study of 2 doses of S\u2010777469 (400 mg BID and 800 mg BID) in patients with atopic dermatitis[Internet]. clinicaltrials.gov; [cited 2021 January 7]. Report No.: NCT00703573.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00703573"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.105.089474"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13958"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.06.005"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2016.07.003"},{"key":"e_1_2_11_142_1","doi-asserted-by":"publisher","DOI":"10.1089\/can.2017.0002"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.04-3010fje"},{"key":"e_1_2_11_144_1","doi-asserted-by":"crossref","unstructured":"Stimulation of cannabinoid receptor 2 (CB 2 ) suppresses microglial activation | Journal of Neuroinflammation | Full Text [Internet]. (2005). [cited 2021 February 23].https:\/\/jneuroinflammation.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/1742\u20102094\u20102\u201029","DOI":"10.1186\/1742-2094-2-29"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-017-0913-7"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.2174\/1570159X16666180702144644"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1002\/wmts.64"},{"key":"e_1_2_11_148_1","unstructured":"The endocannabinoid system in guarding against fear anxiety and stress | Nature Reviews Neuroscience [Internet]. (2015). [cited 2021 January 27].https:\/\/www.nature.com\/articles\/nrn4036"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2009.05.098"},{"key":"e_1_2_11_150_1","doi-asserted-by":"publisher","DOI":"10.1677\/JME-08-0190"},{"key":"e_1_2_11_151_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.01097"},{"key":"e_1_2_11_152_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-019-0114-4"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.2174\/157015909787602823"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12017-014-8314-x"},{"issue":"3","key":"e_1_2_11_155_1","first-page":"1357","article-title":"The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells","volume":"288","author":"Waksman Y.","year":"1999","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"e_1_2_11_156_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2012.06.011"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2017.05.044"},{"key":"e_1_2_11_158_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2015.08.008"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.01.007"},{"key":"e_1_2_11_160_1","doi-asserted-by":"publisher","DOI":"10.5483\/BMBRep.2020.53.1.274"},{"issue":"11","key":"e_1_2_11_161_1","first-page":"4096","article-title":"Activation of cannabinoid receptor type 2 reduces lung ischemia reperfusion injury through PI3K\/Akt pathway","volume":"12","author":"Zeng J.","year":"2019","journal-title":"International Journal of Clinical and Experimental Pathology"},{"key":"e_1_2_11_162_1","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.12101"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tins.2006.07.006"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.1111\/fcp.12008"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.2828"},{"key":"e_1_2_11_166_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms19030833"}],"container-title":["Journal of Neuroscience Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jnr.24933","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/jnr.24933","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jnr.24933","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,28]],"date-time":"2023-08-28T07:01:11Z","timestamp":1693206071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jnr.24933"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,6]]},"references-count":165,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1002\/jnr.24933"],"URL":"https:\/\/doi.org\/10.1002\/jnr.24933","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.1002\/JNR.24933\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JNR.24933\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JNR.24933\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1002\/JNR.24933\/v2\/review1","asserted-by":"object"}]},"ISSN":["0360-4012","1097-4547"],"issn-type":[{"value":"0360-4012","type":"print"},{"value":"1097-4547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,6]]},"assertion":[{"value":"2021-03-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-09-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}